Powder: -20°C for 3 years | In solvent: -80°C for 1 year
trans-AUCB (t-AUCB) 是口服具有活力的、选择性的可溶性环氧水解酶 (sEH) 抑制剂,对人,小鼠和大鼠的 sEH 的IC50分别为 1.3 nM,8 nM,8 nM。它具有抗神经胶质瘤特性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 358 | 待询 | ||
2 mg | ¥ 535 | 待询 | ||
5 mg | ¥ 995 | 待询 | ||
10 mg | ¥ 1,930 | 待询 | ||
25 mg | ¥ 3,530 | 待询 | ||
50 mg | ¥ 4,970 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,150 | 待询 |
产品描述 | trans-AUCB (t-AUCB) is an effective and selective soluble epoxide hydrolase inhibitor (IC50s: 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively). |
靶点活性 | sEH:1.3 Nm(human), sEH:8 nM (mouse), sEH:8 nM (rat) |
体外活性 | trans-AUCB (25-300 μM; 48 hours) inhibits U251 and U87 cell growth in a dose-dependent manner. trans-AUCB (200 μM; 48 hours) suppresses U251 and U87 cell growth by activating NF-jB-p65. trans-AUCB (10 μM; 30 min) efficiently suppresses sEH activities in human glioblastoma cell lines and human hepatocellular carcinoma cell lines. trans-AUCB (200 μM; 48 or 96 hours) induces cell-cycle G0/G1 phase arrest in U251 and U87 cells. trans-AUCB (200 μM; 10 min-4 hours) can increase the phosphorylation levels of p65 after 10 min, reaching to peak after 30 min and lasting for at least 2 hours [1]. |
体内活性 | trans-AUCB (i.v.; 0.1 mg/kg) has t1/2 values of 70 min and 10 hours for distribution (α) and elimination (β) phases. trans-AUCB has a CL of 0.7 L/h?kg and a Vdss was 17 L/kg. trans-AUCB (p.o.; 0.1, 0.5, 1 mg/kg) has t1/2 values of 20, 30, 15 min. trans-AUCB (p.o. of 0.1, 0.5, 1 mg/kg) shows Cmax values of 30, 100, 150 nmol/L. trans-AUCB (t-AUCB; p.o.; 0.1, 0.5, 1 mg/kg) ameliorates the LPS-induced hypotension in a dose-dependent manner. trans-AUCB (s.c.; 1, 3, 10 mg/kg) has t1/2 values of 60, 85, 75 min. trans-AUCB(s.c. of 1, 3, 10 mg/kg) has Cmax values of 245, 2700, 3600 nmol/L [2]. |
别名 | t-AUCB |
分子量 | 412.52 |
分子式 | C24H32N2O4 |
CAS No. | 885012-33-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (242.41 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4241 mL | 12.1206 mL | 24.2412 mL | 60.6031 mL |
5 mM | 0.4848 mL | 2.4241 mL | 4.8482 mL | 12.1206 mL | |
10 mM | 0.2424 mL | 1.2121 mL | 2.4241 mL | 6.0603 mL | |
20 mM | 0.1212 mL | 0.606 mL | 1.2121 mL | 3.0302 mL | |
50 mM | 0.0485 mL | 0.2424 mL | 0.4848 mL | 1.2121 mL | |
100 mM | 0.0242 mL | 0.1212 mL | 0.2424 mL | 0.606 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
trans-AUCB 885012-33-9 Metabolism Epoxide Hydrolase epoxide anti-glioma transAUCB hydrolase t-AUCB activity orally sEH trans AUCB active Inhibitor inhibit soluble inhibitor